Aligos Therapeutics Appoints David Perry as Vice President of Business Development
Aligos Therapeutics, Inc. - Common stock (ALGS)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately. “We are pleased to welcome David to the Aligos team during this exciting time for the company,” said Lesley Ann Calhoun, Executive Vice President and Chief Financial Officer at Aligos. “David’s expertise in leading valuable partnerships will be instrumental as we strategically look to maximize the potential of our best-in-class pipeline, including ALG-055009, which recently announced positive topline data.” “I am excited to join Aligos at this critical time in the Company’s growth, given the significant potential of its clinical stage therapeutics,” stated David Perry, Vice President, Business Development at Aligos. “I look for
Show less
Read more
Impact Snapshot
Event Time:
ALGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALGS alerts
High impacting Aligos Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ALGS
News
- Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024GlobeNewswire
- Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
- Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial ResultsGlobeNewswire
- Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024GlobeNewswire
ALGS
Earnings
- 11/6/24 - Miss
ALGS
Sec Filings
- 11/19/24 - Form EFFECT
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- ALGS's page on the SEC website